image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - IS
$ 7.97
-4.32 %
$ 2.41 B
Market Cap
-9.72
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALVO stock under the worst case scenario is HIDDEN Compared to the current market price of 7.97 USD, Alvotech is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALVO stock under the base case scenario is HIDDEN Compared to the current market price of 7.97 USD, Alvotech is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALVO stock under the best case scenario is HIDDEN Compared to the current market price of 7.97 USD, Alvotech is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALVO

image
$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
490 M REVENUE
435.56%
69.6 M OPERATING INCOME
119.63%
-232 M NET INCOME
57.98%
-237 M OPERATING CASH FLOW
24.13%
-18.9 M INVESTING CASH FLOW
59.28%
297 M FINANCING CASH FLOW
-1.33%
151 M REVENUE
46.96%
13.5 M OPERATING INCOME
5.85%
-67 M NET INCOME
-487.79%
-39.2 M OPERATING CASH FLOW
45.28%
-31.1 M INVESTING CASH FLOW
-136.47%
4.3 M FINANCING CASH FLOW
-97.24%
Balance Sheet Alvotech
image
Current Assets 455 M
Cash & Short-Term Investments 51.4 M
Receivables 252 M
Other Current Assets 152 M
Non-Current Assets 766 M
Long-Term Investments 22.7 M
PP&E 410 M
Other Non-Current Assets 334 M
4.21 %20.61 %12.43 %33.55 %27.34 %Total Assets$1.2b
Current Liabilities 193 M
Accounts Payable 67.1 M
Short-Term Debt 42.2 M
Other Current Liabilities 84.1 M
Non-Current Liabilities 1.44 B
Long-Term Debt 1.15 B
Other Non-Current Liabilities 293 M
4.11 %5.14 %70.25 %17.91 %Total Liabilities$1.6b
EFFICIENCY
Earnings Waterfall Alvotech
image
Revenue 490 M
Cost Of Revenue 185 M
Gross Profit 304 M
Operating Expenses 235 M
Operating Income 69.6 M
Other Expenses 302 M
Net Income -232 M
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)490m(185m)304m(235m)70m(302m)(232m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
62.16% GROSS MARGIN
62.16%
14.22% OPERATING MARGIN
14.22%
-47.35% NET MARGIN
-47.35%
56.17% ROE
56.17%
-18.98% ROA
-18.98%
6.94% ROIC
6.94%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alvotech
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)202020202021202120222022202320232024202420252025
Net Income -232 M
Depreciation & Amortization 31.3 M
Capital Expenditures -57 M
Stock-Based Compensation 7.63 M
Change in Working Capital -289 M
Others 156 M
Free Cash Flow -294 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alvotech
image
Wall Street analysts predict an average 1-year price target for ALVO of $18.5 , with forecasts ranging from a low of $10 to a high of $22 .
ALVO Lowest Price Target Wall Street Target
10 USD 25.47%
ALVO Average Price Target Wall Street Target
18.5 USD 132.12%
ALVO Highest Price Target Wall Street Target
22 USD 176.04%
Price
Max Price Target
Min Price Target
Average Price Target
22222020181816161414121210108866Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Alvotech
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company's product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which currently faces the minimum tariff of 10% on goods imported to the U.S. A 10% tariff on pharmaceuticals would raise the cost of biosimilars from Alvotech imported to the U.S. for customers by less than 1% of Alvotech's expected total product revenues in 2025. Furthermore, according to contracted terms, customers are responsible for all costs of transport and import duties to the U.S., and these costs are therefore not expected to be paid by Alvotech. globenewswire.com - 1 week ago
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company's product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which currently faces the minimum tariff of 10% on goods imported to the U.S. A 10% tariff on pharmaceuticals would raise the cost of biosimilars from Alvotech imported to the U.S. for customers by less than 1% of Alvotech's expected total product revenues in 2025. Furthermore, according to contracted terms, customers are responsible for all costs of transport and import duties to the U.S., and these costs are therefore not expected to be paid by Alvotech. globenewswire.com - 1 week ago
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara® (ustekinumab). As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis. globenewswire.com - 2 weeks ago
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara® (ustekinumab). As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis. globenewswire.com - 2 weeks ago
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).   Live audio of the conference call will be webcast and available to members of the news media, investors, and the general public. globenewswire.com - 2 weeks ago
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).   Live audio of the conference call will be webcast and available to members of the news media, investors, and the general public. globenewswire.com - 2 weeks ago
Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade) Alvotech's stock has dropped significantly due to potential tariffs and ongoing profitability challenges, despite strong revenue growth and a promising biosimilar pipeline. The company's reliance on Icelandic manufacturing and potential US import tariffs create substantial uncertainty, complicating the investment outlook. Alvotech's biosimilars for Humira and Stelara show promise, but competition and market dynamics make profitability elusive. seekingalpha.com - 2 weeks ago
New Strong Sell Stocks for April 25th ALVO, AMPY and ADV have been added to the Zacks Rank #5 (Strong Sell) List on April 25, 2025. zacks.com - 3 weeks ago
New Strong Sell Stocks for April 17th AIRS, XOM and ALVO have been added to the Zacks Rank #5 (Strong Sell) List on April 17, 2025. zacks.com - 1 month ago
This Is a Test From GlobeNewswire This is a test from GlobeNewswire. Readers are advised to disregard. globenewswire.com - 1 month ago
Alvotech (ALVO) Q4 2024 Earnings Call Transcript Alvotech (NASDAQ:ALVO ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Robert Wessman - Chairman, Chief Executive Officer Anil Okay - Chief Commercial Officer Joseph McClellan - Chief Scientific Officer Joel Morales - Chief Financial Officer Benedikt Stefannson - Vice President, Investor Relations Conference Call Participants Ashwani Verma - UBS Operator Good day and thank you for standing by. Welcome to the Alvotech Q4 2024 earnings call. seekingalpha.com - 1 month ago
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. globenewswire.com - 1 month ago
8. Profile Summary

Alvotech ALVO

image
COUNTRY IS
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 2.41 B
Dividend Yield 0.00%
Description Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Contact Saemundargata 15-19, Reykjavik, 102 https://www.alvotech.com
IPO Date June 16, 2022
Employees 1012
Officers Mr. Giedrius Zunda Chief Technical Officer Mr. Anil Okay Chief Commercial Officer Ms. Tanya Zharov General Counsel Mr. Faysal Kalmoua Chief Operating Officer & Director Mr. Anthony M. Maffia III Chief Regulatory Affairs Officer Mr. Benedikt Stefansson Vice President of Investor Relations and Global Communications Mr. Robert Wessman Chief Executive Officer, Founder & Executive Chairman Mr. Joseph E. McClellan Chief Scientific Officer Ms. Jenny Sif Steingrimsdottir Vice President of People & Culture Mr. Joel Morales Chief Financial Officer